Announcement on GMP inspection before EU EMA listing approval
Announcement on the completion of registration for the 2024 Restricted Stock Incentive Plan
Ganli Pharmaceutical Co., Ltd. Capital Inspection Report
Announcement on the receipt of Mexican drug registration approval for insulin glargine injections (pre-filled pens)
Announcement on the resignation of a director
Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Ganli Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Notice to creditors on the repurchase and cancellation of some restricted shares
Announcement on Adjusting the List of Incentive Targets and the Amount Granted for the Company's 2024 Restricted Stock Incentive Plan
Announcement on granting restricted shares to incentive recipients of the 2024 Restricted Stock Incentive Plan
Legal Opinion of Beijing Zhonglun Law Firm on the adjustments and grants related to Ganli Pharmaceutical Co., Ltd.'s 2024 Restricted Stock Incentive Plan
2024 Restricted Stock Incentive Plan Incentive Recipients List (Grant Date)
Announcement of Resolutions of the 19th Meeting of the Fourth Board of Directors
Announcement of Resolutions of the 18th Meeting of the Fourth Board of Supervisors
Verification opinions on matters relating to granting restricted shares to incentive recipients of the Company's 2024 Restricted Stock Incentive Plan
Announcement on plans for senior management to increase their shareholding in the company
Announcement of Resolutions of the 19th Meeting of the Fourth Board of Supervisors
Announcement on the cancellation bill for the 2023 Annual General Meeting of Shareholders
2023 Annual General Meeting of Shareholders Meeting Materials
An indicative announcement on the 2022 Restricted Stock Incentive Plan's first lifting of sales restrictions and the release of sales restrictions and listing circulation
No Data